Construction on the new site is scheduled to begin later this year, with operations expected to start in 2026.

Azita Saleki-Gerhardt, AbbVie executive vice president and chief operations officer, commented: "This expansion announcement represents one of AbbVie's many investments in its Singapore-based operations and the proud continuation of our decade-long partnership with the Government of Singapore."

With this expansion, AbbVie said it has invested more than $740 million in acquiring, modernizing and expanding its Singapore facility over the past ten years. When fully operational, the expanded Singapore manufacturing facility – AbbVie's only manufacturing site in Asia – will employ more than 500 people.